ThermoGenesis (THMO) 10-K 17 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Mar. 15, 2021	Jun. 30, 2020
Document Information [Line Items]
Entity Registrant Name	ThermoGenesis Holdings, Inc.
Entity Central Index Key	0000811212
Trading Symbol	thmo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		11,911,784
Entity Public Float			$ 27,692
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.001 par value

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 7,161,000	$ 3,157,000
Restricted cash		1,000,000
Accounts receivable, net of allowance for doubtful accounts of $214,000 ($226,000 at December 31, 2019)	1,382,000	1,278,000
Inventories	5,877,000	3,484,000
Prepaid expenses and other current assets	878,000	602,000
Total current assets	15,298,000	9,521,000
Inventories, non-current	1,221,000	340,000
Equipment and leasehold improvements, net	1,424,000	2,028,000
Right-of-use operating lease assets, net	730,000	859,000
Goodwill	781,000	781,000
Intangible assets, net	1,358,000	1,467,000
Other assets	48,000	218,000
Total assets	20,860,000	15,214,000
Current liabilities:
Accounts payable	1,366,000	1,447,000
Accrued payroll and related expenses	349,000	288,000
Deferred revenue – short-term	608,000	620,000
Interest payable – related party	2,082,000	1,869,000
Note payable – short-term	447,000
Other current liabilities	1,291,000	2,461,000
Total current liabilities	6,143,000	6,685,000
Convertible promissory note – related party, less debt discount of $4,065,000 ($5,195,000 at December 31, 2019)	5,935,000	3,518,000
Convertible promissory notes, less debt discount of $507,000 (plus debt premium of $46,000 at December 31, 2019)	493,000	413,000
Note payable	199,000	1,000,000
Operating lease obligations – long-term	604,000	761,000
Deferred revenue – long-term	1,596,000	1,901,000
Other noncurrent liabilities	20,000	20,000
Total liabilities	14,990,000	14,298,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 8,934,952 issued and outstanding (2,843,601 at December 31, 2019)	9,000	3,000
Additional paid in capital	259,058,000	237,313,000
Accumulated deficit	(253,283,000)	(236,932,000)
Accumulated other comprehensive loss	16,000	2,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity	5,800,000	386,000
Noncontrolling interests	70,000	530,000
Total equity	5,870,000	916,000
Total liabilities and equity	$ 20,860,000	$ 15,214,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Accounts receivable, allowance for doubtful accounts	$ 214,000	$ 226,000
Debt discount	$ 507,000	$ 46,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	8,934,952	2,843,601
Common stock, shares outstanding (in shares)	8,934,952	2,843,601
Convertible Promissory Note [Member]
Debt discount	$ 4,065,000	$ 5,195,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net revenues	$ 9,705,000	$ 12,160,000
Net revenues – related party	39,000	887,000
Total net revenues	9,744,000	13,047,000
Cost of revenues	8,485,000	7,351,000
Gross profit	1,259,000	5,696,000
Expenses:
Sales and marketing	1,948,000	1,656,000
Research and development	2,477,000	2,396,000
General and administrative	5,729,000	6,377,000
Total operating expenses	10,154,000	10,429,000
Loss from operations	(8,895,000)	(4,733,000)
Other income (expense):
Fair value change of derivative instruments		1,000
Interest expense	(7,908,000)	(4,479,000)
Loss on extinguishment of debt		(840,000)
Loss on equity method investments	(13,000)	(15,000)
Other income (expenses)	5,000	(33,000)
Total other income (expense)	(7,916,000)	(5,366,000)
Net loss	(16,811,000)	(10,099,000)
Loss attributable to non-controlling interests	(460,000)	(602,000)
Net loss attributable to common stockholders	(16,351,000)	(9,497,000)
Net loss	(16,811,000)	(10,099,000)
Other comprehensive loss:
Foreign currency translation adjustments	14,000	15,000
Comprehensive loss	(16,797,000)	(10,084,000)
Comprehensive loss attributable to non-controlling interests	(460,000)	(602,000)
Comprehensive loss attributable to common stockholders	$ (16,337,000)	$ (9,482,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (2.60)	$ (3.36)
Weighted average common shares outstanding Basic and diluted (in shares)	6,277,986	2,828,606

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($)	Boyalife Investment Fund II, Inc. [Member]Common Stock [Member]	Boyalife Investment Fund II, Inc. [Member]Additional Paid-in Capital [Member]	Boyalife Investment Fund II, Inc. [Member]Retained Earnings [Member]	Boyalife Investment Fund II, Inc. [Member]AOCI Attributable to Parent [Member]	[1]	Boyalife Investment Fund II, Inc. [Member]Noncontrolling Interest [Member]	Boyalife Investment Fund II, Inc. [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]		Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2018								2,168,337
Balance at Dec. 31, 2018								$ 2,000	$ 235,888,000	$ (227,435,000)	$ (13,000)	[1]	$ (1,711,000)	$ 6,731,000
Stock-based compensation									614,000					614,000
Exercise of pre-funded warrants (in shares)								416,500
Exercise of pre-funded warrants								$ 1,000	41,000			[1]		42,000
Exercise of warrants (in shares)								18,764
Exercise of warrants									112,000			[1]		112,000
Conversion of note payable to stock (in shares)								240,000
Conversion of note payable to stock									432,000					432,000
Reorganization of subsidiary and related change in non-controlling interest									(2,843,000)				2,843,000
Discount due to beneficial conversion features									2,313,000			[1]		2,313,000
Issuance of common stock pre-funded warrants in financing, net of offering cost									756,000					756,000
Foreign currency translation											15,000			15,000
Net loss										(9,497,000)		[1]	(602,000)	(10,099,000)
Balance (in shares) at Dec. 31, 2019								2,843,601
Balance at Dec. 31, 2019								$ 3,000	237,313,000	(236,932,000)	2,000	[1]	530,000	916,000
Stock-based compensation									880,000			[1]		880,000
Exercise of pre-funded warrants (in shares)								324,445
Exercise of pre-funded warrants									32,000			[1]		32,000
Exercise of warrants (in shares)								275,137
Exercise of warrants									1,651,000			[1]		1,651,000
Conversion of note payable to stock (in shares)	1,666,670							204,445
Conversion of note payable to stock	$ 2,000	$ 2,998,000					$ 3,000,000		368,000			[1]		368,000
Discount due to beneficial conversion features									4,981,000			[1]		4,981,000
Issuance of common stock pre-funded warrants in financing, net of offering cost								4,000	10,835,000					10,839,000
Foreign currency translation											14,000	[1]		14,000
Net loss										(16,351,000)		[1]	(460,000)	(16,811,000)
Sale of common stock, net of fees (in shares)								3,620,654
Balance (in shares) at Dec. 31, 2020								8,934,952
Balance at Dec. 31, 2020								$ 9,000	$ 259,058,000	$ (253,283,000)	$ 16,000	[1]	$ 70,000	$ 5,870,000
[1]	Accumulated other comprehensive loss.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (16,811,000)	$ (10,099,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	742,000	805,000
Stock-based compensation expense	880,000	614,000
Amortization of debt discount/premium, net	5,558,000	2,349,000
Reserve for excess and slow-moving inventories	3,308,000	92,000
Reserve for bad debt expense	(12,000)	(60,000)
Change in fair value of derivative		(1,000)
Loss on disposal of equipment	118,000	70,000
Loss on extinguishment of debt		840,000
Net change in operating assets and liabilities:
Accounts receivable	(90,000)	301,000
Inventories	(6,582,000)	610,000
Prepaid expenses and other assets	(106,000)	(525,000)
Accounts payable	(76,000)	(966,000)
Interest payable - related party	213,000	355,000
Accrued payroll and related expenses	61,000	(415,000)
Deferred revenue	(12,000)	135,000
Other current liabilities	(1,128,000)	1,143,000
Long-term deferred revenue and other noncurrent liabilities	(456,000)	1,492,000
Net cash used in operating activities	(14,393,000)	(3,260,000)
Cash flows from investing activities:
Capital expenditures	(23,000)	(182,000)
Net cash used in investing activities	(23,000)	(182,000)
Cash flows from financing activities:
Proceeds from long-term debt	4,287,000	1,800,000
Proceeds from convertible promissory note-related party		1,513,000
Payments on finance lease obligations	(33,000)	(24,000)
Proceeds from sale of common stock, net of expenses	10,839,000	756,000
Proceeds from exercise of warrants and pre-funded warrants	1,683,000	154,000
Proceeds from note payable	646,000
Net cash provided by financing activities	17,422,000	4,199,000
Effects of foreign currency rate changes on cash and cash equivalents	(2,000)
Net increase in cash, cash equivalents and restricted cash	3,004,000	757,000
Cash, cash equivalents and restricted cash at beginning of period	4,157,000	3,400,000
Cash, cash equivalents and restricted cash at end of period	7,161,000	4,157,000
Supplemental disclosures of cash flow information:
Cash paid for interest	2,379,000	177,000
Supplemental non-cash financing and investing information:
Recording of beneficial conversion feature on debt	4,981,000	2,313,000
Right-to-use asset acquired under operating lease		966,000
Conversion of debt to common stock	3,368,000	432,000
Fair value of amended convertible note issued in connection with the extinguishment of original convertible note		1,473,000
Transfer of equipment to inventories		44,000
Transfer of inventories to equipment		$ 22,000

Note 1 - Description of Busines

Note 1 - Description of Business, Going Concern and Basis of Presentation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business, Going Concern and Basis of Presentation Organization and Basis of Presentation ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”), develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 The Company previously had two 2019, no no no two Clinical Bio-Banking Applications: ● AXP® II Automated Cell Separation System – an automated, fully closed cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood, registered as a U.S. FDA 510 ● BioArchive® Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications, registered as a U.S. FDA 510 Point-of-Care Applications: ● PXP® 510 ● PXP-LAVARE System – an automated, fully closed system that is designed to wash, re-suspend and volume reduce cell suspensions. It allows for volume manipulation, supernatant or media exchange, and cell washing to occur without comprising cell viabilities and maximizing recoveries, registered as a U.S. FDA 510 ● PXP- 1000 510 Large Scale Cell Processing and Biomanufacturing: ● X X X X X ● CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing chimeric antigen receptor (“CAR”) T cell therapies. CAR-TXpress is owned and developed through CARTXpress Bio, Inc. (“CARTXpress Bio”), a subsidiary in which we own 80% On January 1, 2019, July 2017 20% third 20% 80% 100% In the reorganization, the Company reacquired the non-controlling interest shares in ThermoGenesis Corp., in exchange for a 20% $1,100,000. $2,843,000 ThermoGenesis Holdings is an affiliate of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technology and cell-based therapeutics. Reverse Stock Split On June 4, 2019, one 1 ten 10 350,000,000 not All historical share amounts disclosed herein have been retroactively restated to reflect the reverse split and subsequent share exchange. No Liquidity and Going Concern The Company has a Revolving Credit Agreement (the “Credit Agreement”) with Boyalife Asset Holding II, Inc. ( See Note 6 December 31, 2020, $10,000,000 At December 31, 2020, $7,161,000 $9,155,000. December 31, 2020. one may not 19 may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the conditions described herein raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not may Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp's majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. The Company owns 18.79% Non-controlling Interests The 20% not 80%

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Use of Estimates Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, but not Revenue Recognition Revenue is recognized based on the five 606: Step 1 Identify the Contract with the Customer Step 2 Identify Performance Obligations in the Contract not Step 3 Determine the Transaction Price Step 4 Allocate the Transaction Price one Step 5 Satisfaction of the Performance Obligations (and Recognize Revenue) Device Sales Device sales include devices and consumables for BioArchive, AXP, not Service Revenue Service revenue principally consists of maintenance contracts for BioArchive, AXP and CAR-TXpress products. Devices sold have warranty periods of one two one three not Cell Processing Services Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby's birth, with storage revenue recorded as deferred revenue and recognized ratably over the contract term up to 21 December 31, 2020 2019, $216,000 $237,000, December 31, 2020, $8,000 $208,000 may The following table summarizes the revenues by product line: Year Ended December 31, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,774,000 $ 160,000 $ -- $ 4,934,000 BioArchive 855,000 1,177,000 -- 2,032,000 Manual Disposables 599,000 -- -- 599,000 CAR-TXpress 1,471,000 71,000 286,000 1,828,000 Other 289,000 -- 62,000 351,000 Total $ 7,988,000 $ 1,408,000 $ 348,000 $ 9,744,000 Year Ended December 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 7,313,000 $ 209,000 $ -- $ 7,522,000 BioArchive 1,472,000 1,438,000 -- 2,910,000 Manual Disposables 977,000 -- -- 977,000 CAR-TXpress 1,457,000 13,000 95,000 1,565,000 Other -- 22,000 51,000 73,000 Total $ 11,219,000 $ 1,682,000 $ 146,000 $ 13,047,000 Except for limited exceptions in the Company's agreement with its CAR-TXpress distributor, there was no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not December 31, 2020 2019 $620,000 $1,049,000, $608,000 $620,000 December 31, 2020 2019, $1,596,000 $1,901,000 December 31, 2020 2019, Exclusivity Fee On August 30, 2019, five two X $2,000,000 The Company performed an evaluation of the revenue recognition of the $2,000,000 606. $2,000,000 one two five seven seven $286,000 $96,000 December 31, 2020 2019, Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. 2021 2022 2023 2024 2025 2026 and beyond Total Service revenue $ 1,235,000 $ 674,000 $ 412,000 $ 151,000 $ 85,000 $ -- $ 2,557,000 Clinical revenue 13,000 13,000 13,000 14,000 13,000 150,000 216,000 Exclusivity fee 286,000 286,000 286,000 286,000 286,000 188,000 1,618,000 Total $ 1,534,000 $ 973,000 $ 711,000 $ 451,000 $ 384,000 $ 338,000 $ 4,391,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three may $83,000 $10,000 December 31, 2020 2019 not Foreign Currency Translation The Company's reporting currency is the US dollar. The functional currency of the Company's subsidiary in India is the Indian rupee (“INR”). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows are also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows do not $14,000 $15,000 December 31, 2020 2019, Goodwill, Intangible Assets and Impairment Assessments Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Intangible assets that are not three ten For goodwill and indefinite-lived intangible assets, the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not 350 , Intangibles-Goodwill and Other not 50 Fair Value of Financial Instruments In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: 1 not Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company's derivative obligation liability is classified as Level 3 Accounts Receivable and Allowance for Doubtful Accounts The Company's receivables are recorded when billed and represent claims against third may Inventories Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined on the first first not Because some of the Company's products are highly dependent on government and third may may At times, the Company will purchase inventories in larger quantities to obtain volume purchase discounts. In some cases, purchases may not December 31, 2020 December 31, 2019, $1,221,000 $340,000, Equipment and Leasehold Improvements Equipment consisting of machinery and equipment, computers and software, office equipment and leasehold improvements is recorded at cost less accumulated depreciation. Repairs and maintenance costs are expensed as incurred. Depreciation for machinery and equipment, computers and software and office furniture is computed under the straight-line method over the estimated useful lives. Leasehold improvements are amortized under the straight-line method over their estimated useful lives or the remaining lease period, whichever is shorter. When equipment and leasehold improvements are sold or otherwise disposed of, the asset account and related accumulated depreciation account are relieved, and the impact of any resulting gain or loss is recognized within general and administrative expenses in the consolidated statement of operations for the period. Warranty We provide for the estimated cost of product warranties at the time revenue is recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from our estimates, revisions to the estimated warranty liability could have a material impact on our financial position, cash flows or results of operations. Debt Discount and Issue Costs The Company amortizes debt discount and debt issue costs over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method. Derivative Financial Instruments In connection with the sale of convertible debt and equity instruments, the Company may first Stock-Based Compensation We use the Black-Scholes-Merton option-pricing formula in determining the fair value of our options at the grant date and apply judgment in estimating the key assumptions that are critical to the model such as the expected term, volatility and forfeiture rate of an option. Our estimate of these key assumptions is based on historical information and judgment regarding market factors and trends. If any of the key assumptions change significantly, stock-based compensation expense for new awards may The Company has three Note 11 Valuation and Amortization Method – The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The formula does not not Expected Term – For options which the Company has limited available data, the expected term of the option is based on the simplified method. This simplified method averages an award's vesting term and its contractual term. For all other options, the Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected Volatility – Expected volatility is based on historical volatility. Historical volatility is computed using daily pricing observations for recent periods that correspond to the expected term of the options. Expected Dividend – The Company has not not zero Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the valuation method on the implied yield currently available on U.S. Treasury zero Forfeitures – The Company recognizes forfeitures as they occur. Research and Development Research and development costs, consisting of salaries and benefits, costs of disposables, facility costs, contracted services and stock-based compensation from the engineering, regulatory and scientific affairs departments, that are useful in developing and clinically testing new products, services, processes or techniques, as well as expenses for activities that may no Acquired In-Process Research and Development Acquired in-process research and development that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not first not not Patent Costs The costs incurred in connection with patent applications, in defending and maintaining intellectual property rights and litigation proceedings are expensed as incurred. Credit Risk Currently, the Company primarily manufactures and sells cellular processing systems and thermodynamic devices principally to the blood and cellular component processing industry and performs ongoing evaluations of the credit worthiness of the Company's customers. The Company believes that adequate provisions for uncollectible accounts have been made in the accompanying consolidated financial statements. To date, the Company has not Income Taxes The tax years 2000 2019 no no no The Company's estimates of income taxes and the significant items resulting in the recognition of deferred tax assets and liabilities reflect the Company's assessment of future tax consequences of transactions that have been reflected in the financial statements or tax returns for each taxing jurisdiction in which the Company operates. The Company bases the provision for income taxes on the Company's current period results of operations, changes in deferred income tax assets and liabilities, income tax rates, and changes in estimates of uncertain tax positions in the jurisdictions in which the Company operates. The Company recognizes deferred tax assets and liabilities when there are temporary differences between the financial reporting basis and tax basis of assets and liabilities and for the expected benefits of using net operating loss and tax credit loss carryforwards. The Company establishes valuation allowances when necessary to reduce the carrying amount of deferred income tax assets to the amounts that the Company believes are more likely than not one may Income tax consequences that arise in connection with a business combination include identifying the tax basis of assets and liabilities acquired and any contingencies associated with uncertain tax positions assumed or resulting from the business combination. Deferred tax assets and liabilities related to temporary differences of an acquired entity are recorded as of the date of the business combination and are based on the Company's estimate of the appropriate tax basis that will be accepted by the various taxing authorities and its determination as to whether any of the acquired deferred tax liabilities could be a source of taxable income to realize the Company's pre-existing deferred tax assets. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not Recently Adopted Accounting Standards In August 2018, 2018 13, Fair Value Measurement ( Topic 820 ): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement January 1, 2020 not Recently Issued Accounting Standards In August 2020, 2020 06 Debt-Debt with Conversion and Other Options ( Subtopic 470 20 ) and Derivatives and Hedging Contracts in Entity s Own Equity ( Subtopic 815 40 ): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity, 1 2 3 may January 1, 2022 January 1, 2021. In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020, not In June 2016, ASU 2016 13, Topic 326 ). 2016 13 December 15, 2022,

Note 3 - Net Loss Per Share

Note 3 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	3. Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no December 31, 2020, none December 31: 2020 2019 Common stock equivalents of convertible promissory note and accrued interest 7,300,897 6,683,646 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,006,190 1,281,327 Stock options 889,636 291,807 Total 9,307,017 8,367,074 ____________ ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.

Note 4 - Intangible Assets and

Note 4 - Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	4. Intangible Assets and Goodwill In 2020, 350, not not December 31, 2020. no not 2019 3 December 31, 2020 2017. Intangible Assets Goodwill Balance at December 31, 2018, net $ 1,591,000 $ 781,000 Amortization and foreign exchange (124,000 ) -- Balance at December 31, 2019, net $ 1,467,000 $ 781,000 Amortization and foreign exchange (109,000 ) -- Balance at December 31, 2020, net $ 1,358,000 $ 781,000 Intangible assets consist of the following based on the Company's determination of the fair value of identifiable assets acquired: As of December 31, 2020 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Impairment Net Trade names 3 $ 52,000 $ 52,000 $ -- $ -- Developed technology 10 318,000 111,000 -- 207,000 Licenses 7 432,000 424,000 -- 8,000 Device registration 7 66,000 66,000 -- -- Customer relationships 3 442,000 442,000 -- -- Amortizable intangible assets 1,310,000 1,095,000 -- 215,000 In process technology 1,143,000 -- -- 1,143,000 Total $ 2,453,000 $ 1,095,000 $ -- $ 1,358,000 As of December 31, 2019 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Impairment Net Trade names 3 $ 53,000 $ 45,000 $ -- $ 8,000 Developed technology 10 318,000 79,000 -- 239,000 Licenses 7 437,000 367,000 -- 70,000 Device registration 7 66,000 66,000 -- -- Customer relationships 3 443,000 436,000 -- 7,000 Amortizable intangible assets 1,317,000 993,000 -- 324,000 In process technology 1,143,000 -- -- 1,143,000 Total $ 2,460,000 $ 993,000 $ -- $ 1,467,000 The change in the gross carrying amount is due to foreign currency exchange fluctuations. Amortization of intangible assets was $109,000 December 31, 2020 $124,000 December 31, 2019. not not Year Ended December 31, 2021 $ 40,000 2022 32,000 2023 32,000 2024 32,000 2025 32,000 Thereafter 47,000 Total $ 215,000

Note 5 - Equipment and Leasehol

Note 5 - Equipment and Leasehold Improvements, Net	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Equipment and Leasehold Improvements, Net Equipment and leasehold improvements consisted of the following: Year Ended December 31, 2020 2019 Estimated Useful Life (Years) Machinery and equipment $ 6,004,000 $ 6,107,000 2.5 - 10 Computer and software 631,000 631,000 2 - 5 Office equipment 256,000 256,000 5 - 10 Leasehold improvements 932,000 932,000 Shorter of 5 years or remaining lease term Total equipment 7,823,000 7,926,000 Less accumulated depreciation (6,399,000 ) (5,898,000 ) Total equipment and leasehold improvements, net $ 1,424,000 $ 2,028,000 Depreciation expense for the years ended December 31, 2020 2019 $516,000 $574,000,

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	6. Related Party Transactions HealthBanks Biotech (USA) Inc. On November 26, 2019 80% 20% 18.79% first 115% 2018 no $1,000,000 Between November 26, 2019 September 30, 2020, $3,700,000 643,750 $5.00 $16.00 6.05% no 75.16% 18.79% 6.05% The Company initially determined that ImmuneCyte would be considered a variable interest entity, as a result of the significant influence the Company has over operations and its lack of sufficient equity at inception. After the additional investment of $3,700,000, no $28,000, The Company entered into a supply agreement with ImmuneCyte with an effective date of April 22, 2020. 19 one thirty 30 $3,600,000 December 31, 2020. August 2020, $800,000 September 30, 2020. December 31, 2020, $2,800,000. August 2020 19 For the year ended December 31, 2020 December 31, 2019, $13,000 $15,000, December 31, 2020, $0. December 31, 2020, $2,142,000. $1,505,000 $410,000. Convertible Promissory Note and Revolving Credit Agreement In March 2017, $10,000,000 March 6, 2022 ( February 2020, $1,869,000 $3,000,000 1,666,670 two $2,486,000 April 28, 2020, $2,418,000 $10,000,000. $10,000,000 $8,713,000 December 31, 2020 2019, The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% five December 31, 2020, $2,082,000, December 31, 2020. The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include a breach of the Loan documents, termination of operations, or bankruptcy. The Lender's obligation to make advances under the Loan is subject to the Company's representations and warranties in the Credit Agreement continuing to be true at all times and there being no The Credit Agreement and Note were amended in April 2018. $16.10 two 2018, $1.80. It was concluded that the conversion option of the draw down in February 2020 $1,869,000 March 31, 2020. April 2020 $2,418,000 June 30, 2020. $2,931,000 $2,344,000 December 31, 2020 2019, $2,082,000 $1,869,000 December 31, 2020 2019, December 31, 2020 2019 2,082,000 $1,869,000, Distributor Agreement On August 21, 2017, August 20, 2020. During the year ended December 31, 2020, $14,000 $10,000 December 31, 2020. December 31, 2019, $794,000 $20,000 December 31, 2019.

Note 7 - Convertible Promissory

Note 7 - Convertible Promissory Notes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Convertible Promissory Notes January 2019 On January 29, 2019, $800,000 “January 2019 six $1.80 90% $0.50 The January 2019 twenty-four 24% January 2019 eighteen 18 January 2019 On the date that is six January 2019 January 2019 January 2019 may January 2019 January 2019 4.99% 9.99% $800,000, May 30, 2019. On July 23, 2019, No. 1 January 2019 January 2019 July 29, 2020 July 31, 2022. January 2019 January 2019 January 2019 10% January 2019 $840,000 December 31, 2019. $1,473,000 $556,000 December 31, 2019. $77,000 January 2019 December 31, 2019. Stock price at date of issuance $ 3.05 Exercise price (1) $ 1.80 Risk-free interest rate 1.8 % Expected dividend yield -- Expected term (in years) 3.02 Expected volatility 93 % __________________ ( 1 For the exercise price, the model inputs also accounted for the fair value protection under the Amended Note, which allows for the holder to convert at the lower of $1.80 90% $0.50 During the year ended December 31, 2020, December 31, 2020, $368,000 204,445 $46,000 December 31, 2020. During the year ended December 31, 2019, $432,000 240,000 $60,000 December 31, 2019. On July 23, 2019, $1,000,000 “July 2019 six July 2019 $1.80 90% $0.50 July 2019 twenty-four 24% July 2019 three July 31, 2022. The July 2019 may six July 2019 may July 2019 July 2019 $694,000, June 4, 2020.

Note 8 - Payment Protection Pro

Note 8 - Payment Protection Program	12 Months Ended
	Dec. 31, 2020
Paycheck Protection Program CARES Act [Member]
Notes to Financial Statements
Long-term Debt [Text Block]	8. Payment Protection Program On April 21, 2020, $646,000 two 1.00% first six may may December 2020, 90 December 2020, $447,000, $199,000.

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies Financial Covenants On July 13, 2020, #2 July 13, 2020 ( May 15, 2017 #1 March 16, 2020 one $1,000,000 December 31, 2020. Potential Severance Payments We have entered into an employment agreement with the Company Chief Executive Officer under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason. Contingencies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 August 2016. October 2017, $1,000,000 February 2020 $1,000,000. $1,400,000 December 31, 2019. $1,000,000 $400,000 $1,000,000 May 1, 2020 $480,000, $369,000 $111,000 not $1,000,000 In the normal course of operations, the Company may December 31, 2020, may not Warranty The Company offers a warranty on all of its non-disposable products of one two three The warranty liability is included in other current liabilities in the consolidated balance sheets. Changes in the Company's warranty reserve, which is included in other current liabilities in the accompanying consolidated balance sheet is as follows: Year Ended December 31, 2020 2019 Beginning balance $ 277,000 $ 186,000 Warranties originated during the year 71,000 254,000 Claims settled made during the year (212,000 ) (154,000 ) Changes in reserve estimate 18,000 (9,000 ) Ending balance $ 154,000 $ 277,000

Note 10 - Leases

Note 10 - Leases	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. Leases Operating Leases The Company leases its Rancho Cordova, California corporate headquarters. The lease expires in May 2024. 842. December 31, 2020. The operating lease assets and liabilities were recognized at the lease commencement date. The operating lease liabilities represent the present value of remaining minimum lease payments. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not The following summarizes the Company's operating leases: Year Ended December 31, 2020 2019 Right-of-use operating lease assets, net $ 730,000 $ 859,000 Current lease liability 157,000 118,000 Non-current lease liability 604,000 761,000 Weighted average remaining lease term 3.4 4.4 Discount rate 22 % 22 % Maturities of lease liabilities by calendar year for our operating leases are as follows: 2021 310,000 2022 319,000 2023 328,000 2024 139,000 2025 -- Thereafter -- Total lease payment $ 1,096,000 Less: imputed interest (335,000 ) Present value of operating lease liabilities $ 761,000 Statement of Cash Flows In January 2019, $966,000 $301,000 $291,000 December 31, 2020 2019, Operating Lease Costs Operating lease costs were $450,000 December 31, 2020, $182,000 $129,000 $111,000 $28,000 $410,000 December 31, 2019, $204,000 $108,000 $72,000 $26,000 30 Finance Leases Finance leases are included in equipment and other current and non-current liabilities in the accompanying consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively in the accompanying statements of operations. As of December 31, 2020 2019,

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	11. Stockholders Equity Common Stock On March 25, 2020, three 1,000,002 $3.50 $3,500,000 $393,000 On December 13, 2019, may $4,400,000 May 19, 2020 $15,280,313 December 31, 2020, 2,620,652 $8,224,000 $3.14 $7,731,000 $493,000. On April 18, 2019, “April 444,445 $1.70 one $0.10 $756,000. April April 26, 2019 April three sixty-five 365 December 31, 2020, April Warrants A summary of warrant activity is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contract Term Balance at January 1, 2019 1,726,522 $ 29.88 2.20 Warrants granted 444,445 $ 0.10 Warrants exercised (435,264 ) $ 0.35 Warrants expired/canceled (19,637 ) Outstanding at December 31, 2019 1,716,066 $ 25.23 1.57 Exercisable at December 31, 2019 1,646,214 $ 22.91 1.63 Balance at January 1, 2020 1,716,066 $ 25.23 1.57 Warrants granted -- $ -- Warrants exercised (599,582 ) $ 2.81 Warrants expired/canceled -- Outstanding at December 31, 2020 1,116,484 $ 37.27 0.49 Exercisable at December 31, 2020 1,046,631 $ 34.42 0.54 Equity Plans and Agreements The Amended 2016 2016 May 2017, 600,000 may June 22, 2018, 2016 may 1,325,000 May 30, 2019, 2016 may 1,325,000 3,925,000 December 31, 2020, 386,436 2016 The 2012 “2012 2,500 2012 100% not ten one December 31, 2020, 234 On December 29, 2017, 2017 280,000 December 29, 2017. 1,000,000 20,000 December 31, 2020. On June 4, 2020, 565,500 $5.94 four first four 2016 2021 Stock Based Compensation The Company recorded stock-based compensation of $880,000 December 31, 2020 $614,000 December 31, 2019, Year Ended December 31, 2020 2019 Cost of revenues $ 9,000 $ 3,000 Sales and marketing 176,000 185,000 Research and development 114,000 98,000 General and administrative 581,000 328,000 $ 880,000 $ 614,000 Stock Options The Company issues new shares of common stock upon exercise of stock options. The following is a summary of option activity for the Company's stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at January 1, 2020 291,807 $ 13.96 8.3 $ 280,000 Granted 615,500 $ 5.92 Forfeited/cancelled (17,671 ) $ 5.63 $ 1,840 Outstanding at December 31, 2020 889,636 $ 8.57 8.7 $ -- Vested and Expected to Vest at December 31, 2020 598,092 $ 9.72 8.5 $ -- Exercisable at December 31, 2020 230,836 $ 15.21 7.5 $ -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company's common stock. Non-vested stock option activity for the year ended December 31, 2020, Non-vested Stock Options Weighted-Average Grant Date Fair Value Outstanding at January 1, 2020 144,683 $ 6.38 Granted 615,500 $ 5.05 Vested (88,683 ) $ 5.72 Cancelled/forfeited (12,700 ) $ 4.82 Outstanding at December 31, 2020 658,800 $ 5.25 The fair value of the Company's stock options granted for the years ended December 31, 2020 December 31, 2019 Year Ended December 31, 2020 2019 Expected life (years) 6 5 Expected volatility 116% 103% Risk-free interest rate 0.54% 1.68% Dividend yield 0% 0% The weighted average grant date fair value of options granted during the years ended December 31, 2020 2019 $5.05 $3.30 At December 31, 2020, not $2,148,000. three

Note 12 - Concentrations

Note 12 - Concentrations	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	12. Concentrations One customer had an accounts receivable balance of $531,000 38% $337,000 27% December 31, 2020 2019, $2,646,000 27% $3,575,000 27% December 31, 2020 2019, $337,000 24% $0 December 31, 2020 2019, $1,293,000 13% $0 December 31, 2020 2019, second $139,000 10% $93,000 7% December 31, 2020 2019, $283,000 3% 373,000 3% December 31, 2020 2019, One supplier accounted for 40% 57% December 31, 2020 2019, The Company has a contract manufacturer in Costa Rica that produces certain disposables. The Company's equipment and leasehold improvements, net of accumulated depreciation, is summarized below by geographic area: Year Ended December 31, 2020 2019 United States $ 810,000 $ 1,108,000 Costa Rica 390,000 582,000 India 169,000 225,000 All other countries 55,000 113,000 Total equipment, net $ 1,424,000 $ 2,028,000

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes Loss before income tax benefits was comprised of $16,728,000 $83,000 December 31, 2020 $9,949,000 $150,000 December 31, 2019. The reconciliation of federal income tax attributable to operations computed at the federal statutory tax rate to income tax benefit is as follows for the: Year Ended December 31, 2020 2019 Statutory federal income tax benefit $ (3,530,000 ) $ (2,118,000 ) Intangible assets 69,000 673,000 Change in valuation allowance 197,000 (681,000 ) Expiration of net operating losses 1,558,000 1,187,000 Disallowed financing costs 1,619,000 1,119,000 State and local taxes (18,000 ) (205,000 ) Other 105,000 25,000 Total income tax expense $ -- $ -- At December 31, 2020, $126,582,000 $106,226,000 2037 $20,356,000 $41,511,000 may 2040. $796,000 may 2027. At December 31, 2020, $1,601,000 2021 2040, $1,583,000 not 2031 2032. Significant components of the Company's deferred tax assets and liabilities for federal and state income taxes are as follows: Year Ended December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 27,312,000 $ 26,758,000 Income tax credit carryforwards 2,852,000 2,757,000 Stock compensation 369,000 384,000 Lease obligation 160,000 185,000 Deferred revenue 340,000 419,000 Other 528,000 943,000 Total deferred tax assets 31,561,000 31,446,000 Deferred tax liabilities Depreciation and amortization (352,000 ) (408,000 ) Lease asset (153,000 ) (180,000 ) Total deferred tax liabilities (505,000 ) (588,000 ) Valuation allowance (31,056,000 ) (30,858,000 ) Net deferred taxes $ -- $ -- ASC 740 not." not The valuation allowance increased by $197,000 $681,000 December 31, 2020 2019, The transition tax is based on total post- 1986 December 31, 2020, not no not not In August 2016, 1986. may 2016 2016 2020. On March 27, 2020, 163 1986, 2019 2020 168 2018, 2019, 2020 five December 31, 2020, not not 2020 2020. On June 29, 2020, AB85 2020 2022. 2020, not

Note 14 - Employee Retirement P

Note 14 - Employee Retirement Plan	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Retirement Benefits [Text Block]	14. Employee Retirement Plan In January 2020, 401 may may $147,000 $0 December 31, 2020 2019,

Note 15 - Subsequent Events

Note 15 - Subsequent Events	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	15. Subsequent Events The Company has evaluated events subsequent to the balance sheet date for inclusion in the accompanying consolidated financial statements through the date of issuance and determined that no Subsequent to December 31, 2020, 2,976,832 $7,056,000 $2.37 $6,832,000 $224,000. In March 2021, 18.79% 8.8%.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, but not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606: Step 1 Identify the Contract with the Customer Step 2 Identify Performance Obligations in the Contract not Step 3 Determine the Transaction Price Step 4 Allocate the Transaction Price one Step 5 Satisfaction of the Performance Obligations (and Recognize Revenue) Device Sales Device sales include devices and consumables for BioArchive, AXP, not Service Revenue Service revenue principally consists of maintenance contracts for BioArchive, AXP and CAR-TXpress products. Devices sold have warranty periods of one two one three not Cell Processing Services Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby's birth, with storage revenue recorded as deferred revenue and recognized ratably over the contract term up to 21 December 31, 2020 2019, $216,000 $237,000, December 31, 2020, $8,000 $208,000 may The following table summarizes the revenues by product line: Year Ended December 31, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,774,000 $ 160,000 $ -- $ 4,934,000 BioArchive 855,000 1,177,000 -- 2,032,000 Manual Disposables 599,000 -- -- 599,000 CAR-TXpress 1,471,000 71,000 286,000 1,828,000 Other 289,000 -- 62,000 351,000 Total $ 7,988,000 $ 1,408,000 $ 348,000 $ 9,744,000 Year Ended December 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 7,313,000 $ 209,000 $ -- $ 7,522,000 BioArchive 1,472,000 1,438,000 -- 2,910,000 Manual Disposables 977,000 -- -- 977,000 CAR-TXpress 1,457,000 13,000 95,000 1,565,000 Other -- 22,000 51,000 73,000 Total $ 11,219,000 $ 1,682,000 $ 146,000 $ 13,047,000 Except for limited exceptions in the Company's agreement with its CAR-TXpress distributor, there was no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not December 31, 2020 2019 $620,000 $1,049,000, $608,000 $620,000 December 31, 2020 2019, $1,596,000 $1,901,000 December 31, 2020 2019, Exclusivity Fee On August 30, 2019, five two X $2,000,000 The Company performed an evaluation of the revenue recognition of the $2,000,000 606. $2,000,000 one two five seven seven $286,000 $96,000 December 31, 2020 2019, Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. 2021 2022 2023 2024 2025 2026 and beyond Total Service revenue $ 1,235,000 $ 674,000 $ 412,000 $ 151,000 $ 85,000 $ -- $ 2,557,000 Clinical revenue 13,000 13,000 13,000 14,000 13,000 150,000 216,000 Exclusivity fee 286,000 286,000 286,000 286,000 286,000 188,000 1,618,000 Total $ 1,534,000 $ 973,000 $ 711,000 $ 451,000 $ 384,000 $ 338,000 $ 4,391,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three may $83,000 $10,000 December 31, 2020 2019 not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The Company's reporting currency is the US dollar. The functional currency of the Company's subsidiary in India is the Indian rupee (“INR”). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows are also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows do not $14,000 $15,000 December 31, 2020 2019,
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill, Intangible Assets and Impairment Assessments Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Intangible assets that are not three ten For goodwill and indefinite-lived intangible assets, the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not 350 , Intangibles-Goodwill and Other not 50
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: 1 not Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company's derivative obligation liability is classified as Level 3
Receivable [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts The Company's receivables are recorded when billed and represent claims against third may
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined on the first first not Because some of the Company's products are highly dependent on government and third may may At times, the Company will purchase inventories in larger quantities to obtain volume purchase discounts. In some cases, purchases may not December 31, 2020 December 31, 2019, $1,221,000 $340,000,
Property, Plant and Equipment, Policy [Policy Text Block]	Equipment and Leasehold Improvements Equipment consisting of machinery and equipment, computers and software, office equipment and leasehold improvements is recorded at cost less accumulated depreciation. Repairs and maintenance costs are expensed as incurred. Depreciation for machinery and equipment, computers and software and office furniture is computed under the straight-line method over the estimated useful lives. Leasehold improvements are amortized under the straight-line method over their estimated useful lives or the remaining lease period, whichever is shorter. When equipment and leasehold improvements are sold or otherwise disposed of, the asset account and related accumulated depreciation account are relieved, and the impact of any resulting gain or loss is recognized within general and administrative expenses in the consolidated statement of operations for the period.
Standard Product Warranty, Policy [Policy Text Block]	Warranty We provide for the estimated cost of product warranties at the time revenue is recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from our estimates, revisions to the estimated warranty liability could have a material impact on our financial position, cash flows or results of operations.
Debt, Policy [Policy Text Block]	Debt Discount and Issue Costs The Company amortizes debt discount and debt issue costs over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method.
Derivatives, Policy [Policy Text Block]	Derivative Financial Instruments In connection with the sale of convertible debt and equity instruments, the Company may first
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation We use the Black-Scholes-Merton option-pricing formula in determining the fair value of our options at the grant date and apply judgment in estimating the key assumptions that are critical to the model such as the expected term, volatility and forfeiture rate of an option. Our estimate of these key assumptions is based on historical information and judgment regarding market factors and trends. If any of the key assumptions change significantly, stock-based compensation expense for new awards may The Company has three Note 11 Valuation and Amortization Method – The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The formula does not not Expected Term – For options which the Company has limited available data, the expected term of the option is based on the simplified method. This simplified method averages an award's vesting term and its contractual term. For all other options, the Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected Volatility – Expected volatility is based on historical volatility. Historical volatility is computed using daily pricing observations for recent periods that correspond to the expected term of the options. Expected Dividend – The Company has not not zero Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the valuation method on the implied yield currently available on U.S. Treasury zero Forfeitures – The Company recognizes forfeitures as they occur.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs, consisting of salaries and benefits, costs of disposables, facility costs, contracted services and stock-based compensation from the engineering, regulatory and scientific affairs departments, that are useful in developing and clinically testing new products, services, processes or techniques, as well as expenses for activities that may no
Business Combinations Policy [Policy Text Block]	Acquired In-Process Research and Development Acquired in-process research and development that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not first not not
Legal Costs, Policy [Policy Text Block]	Patent Costs The costs incurred in connection with patent applications, in defending and maintaining intellectual property rights and litigation proceedings are expensed as incurred.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Currently, the Company primarily manufactures and sells cellular processing systems and thermodynamic devices principally to the blood and cellular component processing industry and performs ongoing evaluations of the credit worthiness of the Company's customers. The Company believes that adequate provisions for uncollectible accounts have been made in the accompanying consolidated financial statements. To date, the Company has not
Income Tax, Policy [Policy Text Block]	Income Taxes The tax years 2000 2019 no no no The Company's estimates of income taxes and the significant items resulting in the recognition of deferred tax assets and liabilities reflect the Company's assessment of future tax consequences of transactions that have been reflected in the financial statements or tax returns for each taxing jurisdiction in which the Company operates. The Company bases the provision for income taxes on the Company's current period results of operations, changes in deferred income tax assets and liabilities, income tax rates, and changes in estimates of uncertain tax positions in the jurisdictions in which the Company operates. The Company recognizes deferred tax assets and liabilities when there are temporary differences between the financial reporting basis and tax basis of assets and liabilities and for the expected benefits of using net operating loss and tax credit loss carryforwards. The Company establishes valuation allowances when necessary to reduce the carrying amount of deferred income tax assets to the amounts that the Company believes are more likely than not one may Income tax consequences that arise in connection with a business combination include identifying the tax basis of assets and liabilities acquired and any contingencies associated with uncertain tax positions assumed or resulting from the business combination. Deferred tax assets and liabilities related to temporary differences of an acquired entity are recorded as of the date of the business combination and are based on the Company's estimate of the appropriate tax basis that will be accepted by the various taxing authorities and its determination as to whether any of the acquired deferred tax liabilities could be a source of taxable income to realize the Company's pre-existing deferred tax assets.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In August 2018, 2018 13, Fair Value Measurement ( Topic 820 ): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement January 1, 2020 not Recently Issued Accounting Standards In August 2020, 2020 06 Debt-Debt with Conversion and Other Options ( Subtopic 470 20 ) and Derivatives and Hedging Contracts in Entity s Own Equity ( Subtopic 815 40 ): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity, 1 2 3 may January 1, 2022 January 1, 2021. In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020, not In June 2016, ASU 2016 13, Topic 326 ). 2016 13 December 15, 2022,

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,774,000 $ 160,000 $ -- $ 4,934,000 BioArchive 855,000 1,177,000 -- 2,032,000 Manual Disposables 599,000 -- -- 599,000 CAR-TXpress 1,471,000 71,000 286,000 1,828,000 Other 289,000 -- 62,000 351,000 Total $ 7,988,000 $ 1,408,000 $ 348,000 $ 9,744,000 Year Ended December 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 7,313,000 $ 209,000 $ -- $ 7,522,000 BioArchive 1,472,000 1,438,000 -- 2,910,000 Manual Disposables 977,000 -- -- 977,000 CAR-TXpress 1,457,000 13,000 95,000 1,565,000 Other -- 22,000 51,000 73,000 Total $ 11,219,000 $ 1,682,000 $ 146,000 $ 13,047,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	2021 2022 2023 2024 2025 2026 and beyond Total Service revenue $ 1,235,000 $ 674,000 $ 412,000 $ 151,000 $ 85,000 $ -- $ 2,557,000 Clinical revenue 13,000 13,000 13,000 14,000 13,000 150,000 216,000 Exclusivity fee 286,000 286,000 286,000 286,000 286,000 188,000 1,618,000 Total $ 1,534,000 $ 973,000 $ 711,000 $ 451,000 $ 384,000 $ 338,000 $ 4,391,000

Note 3 - Net Loss Per Share (Ta

Note 3 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2020 2019 Common stock equivalents of convertible promissory note and accrued interest 7,300,897 6,683,646 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,006,190 1,281,327 Stock options 889,636 291,807 Total 9,307,017 8,367,074

Note 4 - Intangible Assets an_2

Note 4 - Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	Intangible Assets Goodwill Balance at December 31, 2018, net $ 1,591,000 $ 781,000 Amortization and foreign exchange (124,000 ) -- Balance at December 31, 2019, net $ 1,467,000 $ 781,000 Amortization and foreign exchange (109,000 ) -- Balance at December 31, 2020, net $ 1,358,000 $ 781,000
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of December 31, 2020 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Impairment Net Trade names 3 $ 52,000 $ 52,000 $ -- $ -- Developed technology 10 318,000 111,000 -- 207,000 Licenses 7 432,000 424,000 -- 8,000 Device registration 7 66,000 66,000 -- -- Customer relationships 3 442,000 442,000 -- -- Amortizable intangible assets 1,310,000 1,095,000 -- 215,000 In process technology 1,143,000 -- -- 1,143,000 Total $ 2,453,000 $ 1,095,000 $ -- $ 1,358,000 As of December 31, 2019 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Impairment Net Trade names 3 $ 53,000 $ 45,000 $ -- $ 8,000 Developed technology 10 318,000 79,000 -- 239,000 Licenses 7 437,000 367,000 -- 70,000 Device registration 7 66,000 66,000 -- -- Customer relationships 3 443,000 436,000 -- 7,000 Amortizable intangible assets 1,317,000 993,000 -- 324,000 In process technology 1,143,000 -- -- 1,143,000 Total $ 2,460,000 $ 993,000 $ -- $ 1,467,000
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ended December 31, 2021 $ 40,000 2022 32,000 2023 32,000 2024 32,000 2025 32,000 Thereafter 47,000 Total $ 215,000

Note 5 - Equipment and Leaseh_2

Note 5 - Equipment and Leasehold Improvements, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	Year Ended December 31, 2020 2019 Estimated Useful Life (Years) Machinery and equipment $ 6,004,000 $ 6,107,000 2.5 - 10 Computer and software 631,000 631,000 2 - 5 Office equipment 256,000 256,000 5 - 10 Leasehold improvements 932,000 932,000 Shorter of 5 years or remaining lease term Total equipment 7,823,000 7,926,000 Less accumulated depreciation (6,399,000 ) (5,898,000 ) Total equipment and leasehold improvements, net $ 1,424,000 $ 2,028,000

Note 7 - Convertible Promisso_2

Note 7 - Convertible Promissory Notes (Tables)	12 Months Ended
	Dec. 31, 2020
Convertible Debt [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Stock price at date of issuance $ 3.05 Exercise price (1) $ 1.80 Risk-free interest rate 1.8 % Expected dividend yield -- Expected term (in years) 3.02 Expected volatility 93 %

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Year Ended December 31, 2020 2019 Beginning balance $ 277,000 $ 186,000 Warranties originated during the year 71,000 254,000 Claims settled made during the year (212,000 ) (154,000 ) Changes in reserve estimate 18,000 (9,000 ) Ending balance $ 154,000 $ 277,000

Note 10 - Leases (Tables)

Note 10 - Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Lease, Cost [Table Text Block]	Year Ended December 31, 2020 2019 Right-of-use operating lease assets, net $ 730,000 $ 859,000 Current lease liability 157,000 118,000 Non-current lease liability 604,000 761,000 Weighted average remaining lease term 3.4 4.4 Discount rate 22 % 22 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 310,000 2022 319,000 2023 328,000 2024 139,000 2025 -- Thereafter -- Total lease payment $ 1,096,000 Less: imputed interest (335,000 ) Present value of operating lease liabilities $ 761,000

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contract Term Balance at January 1, 2019 1,726,522 $ 29.88 2.20 Warrants granted 444,445 $ 0.10 Warrants exercised (435,264 ) $ 0.35 Warrants expired/canceled (19,637 ) Outstanding at December 31, 2019 1,716,066 $ 25.23 1.57 Exercisable at December 31, 2019 1,646,214 $ 22.91 1.63 Balance at January 1, 2020 1,716,066 $ 25.23 1.57 Warrants granted -- $ -- Warrants exercised (599,582 ) $ 2.81 Warrants expired/canceled -- Outstanding at December 31, 2020 1,116,484 $ 37.27 0.49 Exercisable at December 31, 2020 1,046,631 $ 34.42 0.54
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, 2020 2019 Cost of revenues $ 9,000 $ 3,000 Sales and marketing 176,000 185,000 Research and development 114,000 98,000 General and administrative 581,000 328,000 $ 880,000 $ 614,000
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at January 1, 2020 291,807 $ 13.96 8.3 $ 280,000 Granted 615,500 $ 5.92 Forfeited/cancelled (17,671 ) $ 5.63 $ 1,840 Outstanding at December 31, 2020 889,636 $ 8.57 8.7 $ -- Vested and Expected to Vest at December 31, 2020 598,092 $ 9.72 8.5 $ -- Exercisable at December 31, 2020 230,836 $ 15.21 7.5 $ --
Non Vested Stock Options Activity [Table Text Block]	Non-vested Stock Options Weighted-Average Grant Date Fair Value Outstanding at January 1, 2020 144,683 $ 6.38 Granted 615,500 $ 5.05 Vested (88,683 ) $ 5.72 Cancelled/forfeited (12,700 ) $ 4.82 Outstanding at December 31, 2020 658,800 $ 5.25
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2020 2019 Expected life (years) 6 5 Expected volatility 116% 103% Risk-free interest rate 0.54% 1.68% Dividend yield 0% 0%

Note 12 - Concentrations (Table

Note 12 - Concentrations (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]	Year Ended December 31, 2020 2019 United States $ 810,000 $ 1,108,000 Costa Rica 390,000 582,000 India 169,000 225,000 All other countries 55,000 113,000 Total equipment, net $ 1,424,000 $ 2,028,000

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2020 2019 Statutory federal income tax benefit $ (3,530,000 ) $ (2,118,000 ) Intangible assets 69,000 673,000 Change in valuation allowance 197,000 (681,000 ) Expiration of net operating losses 1,558,000 1,187,000 Disallowed financing costs 1,619,000 1,119,000 State and local taxes (18,000 ) (205,000 ) Other 105,000 25,000 Total income tax expense $ -- $ --
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Year Ended December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 27,312,000 $ 26,758,000 Income tax credit carryforwards 2,852,000 2,757,000 Stock compensation 369,000 384,000 Lease obligation 160,000 185,000 Deferred revenue 340,000 419,000 Other 528,000 943,000 Total deferred tax assets 31,561,000 31,446,000 Deferred tax liabilities Depreciation and amortization (352,000 ) (408,000 ) Lease asset (153,000 ) (180,000 ) Total deferred tax liabilities (505,000 ) (588,000 ) Valuation allowance (31,056,000 ) (30,858,000 ) Net deferred taxes $ -- $ --

Note 1 - Description of Busin_2

Note 1 - Description of Business, Going Concern and Basis of Presentation (Details Textual)	Jun. 04, 2019shares	Jan. 01, 2019USD ($)	Dec. 31, 2019USD ($)shares	Dec. 31, 2020USD ($)shares	Sep. 30, 2020	Apr. 28, 2020USD ($)	Nov. 26, 2019
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance			$ 530,000	$ 70,000
Reorganization of Subsidiary and Related Change in Non-controlling Interest
Common Stock, Shares Authorized (in shares) | shares	350,000,000		350,000,000	350,000,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance			$ 3,157,000	$ 7,161,000
Working Capital				$ 9,155,000
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage				18.79%	18.79%		20.00%
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Long-term Line of Credit, Total			8,713,000	$ 10,000,000		$ 10,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10
Noncontrolling Interest [Member]
Reorganization of Subsidiary and Related Change in Non-controlling Interest		$ 2,843,000	$ 2,843,000
CAR-TXpress [Member]
Noncontrolling Interest, Ownership Percentage by Parent		80.00%		80.00%
Minority Interest Acquired Through Exchange		20.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance		$ 1,100,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners				20.00%
ThermoGenesis [Member]
Noncontrolling Interest, Ownership Percentage by Parent		100.00%
Ownership in Subsidiary Exchanged		20.00%

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Aug. 30, 2019	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Contract with Customer, Liability, Revenue Recognized			$ 620,000	$ 1,049,000
Deferred Revenue, Current, Total			608,000	620,000
Deferred Revenue, Noncurrent, Total			1,596,000	1,901,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance			7,161,000	3,157,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total			14,000	15,000
Inventory, Noncurrent, Total			1,221,000	340,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments			0
Income Tax Examination, Penalties and Interest Accrued, Total			0
Unrecognized Tax Benefits, Ending Balance			$ 0
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			3 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			10 years
INDIA
Cash and Cash Equivalents, at Carrying Value, Ending Balance			$ 83,000	10,000
Exclusivity Fee [Member]
Contract with Customer, Liability, Revenue Recognized			286,000	96,000
Supply Agreement [Member]
Contract with Customer, Liability, Total	$ 2,000,000
Supply Agreement, Term (Year)	5 years
Supply Agreement, Renewal Term (Year)	2 years	2 years
Cord Blood Storage Revenue [Member]
Contract with Customer, Liability, Total			216,000	$ 237,000
Contract with Customer, Liability, Current			8,000
Contract with Customer, Liability, Noncurrent			$ 208,000
Exclusivity Fee [Member]
Exclusivity Fee Recognize Period (Year)		7 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net revenues	$ 9,744,000	$ 13,047,000
Device [Member] | AXP [Member]
Net revenues	4,934,000	7,522,000
Device [Member] | BioArchive [Member]
Net revenues	2,032,000	2,910,000
Device [Member] | Manual Disposables [Member]
Net revenues	599,000	977,000
Device [Member] | CAR-TXpress [Member]
Net revenues	1,828,000	1,565,000
Device [Member] | Other Subsegments [Member]
Net revenues	351,000	73,000
Device Revenue [Member]
Net revenues	7,988,000	11,219,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	4,774,000	7,313,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	855,000	1,472,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	599,000	977,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	1,471,000	1,457,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	289,000
Service [Member]
Net revenues	1,408,000	1,682,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	160,000	209,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	1,177,000	1,438,000
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	71,000	13,000
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues		22,000
Other [Member]
Net revenues	348,000	146,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	286,000	95,000
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	$ 62,000	$ 51,000

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Dec. 31, 2020USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,391,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	2,557,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	216,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,618,000

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details)	Dec. 31, 2020USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,391,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,534,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 973,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 711,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 451,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 384,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 338,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 2,557,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,235,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 674,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 412,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 151,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 85,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 216,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 150,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,618,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 188,000

Note 3 - Net Loss Per Share - A

Note 3 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Anti-dilutive securities (in shares)		9,307,017	8,367,074
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		7,300,897	6,683,646
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		40,441	40,441
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	69,853	69,853
Warrant, Other [Member]
Anti-dilutive securities (in shares)		1,006,190	1,281,327
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)		889,636	291,807
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 4 - Intangible Assets an_3

Note 4 - Intangible Assets and Goodwill (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Amortization of Intangible Assets, Total	$ 109,000	$ 124,000

Note 4 - Intangible Assets an_4

Note 4 - Intangible Assets and Goodwill - Goodwill and Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Intangible assets, net	$ 1,467,000	$ 1,591,000
Goodwill	781,000	781,000
Intangible assets, amortization and foreign exchange	(109,000)	(124,000)
Goodwill, foreign exchange
Intangible assets, net	1,358,000	1,467,000
Goodwill	$ 781,000	$ 781,000

Note 4 - Intangible Assets an_5

Note 4 - Intangible Assets and Goodwill - Summary of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Gross Carrying Amount	$ 1,310,000	$ 1,317,000
Accumulated Amortization	1,095,000	993,000
Net	215,000	324,000
Impairment
Gross Carrying Amount	2,453,000	2,460,000
Impairment
Net	1,358,000	1,467,000	$ 1,591,000
In Process Techonology [Member]
Gross Carrying Amount	1,143,000	1,143,000
Impairment
Net	$ 1,143,000	$ 1,143,000
Trade Names [Member]
Weighted Average Amortization Period (Year)	3 years	3 years
Gross Carrying Amount	$ 52,000	$ 53,000
Accumulated Amortization	52,000	45,000
Net		$ 8,000
Developed Technology Rights [Member]
Weighted Average Amortization Period (Year)	10 years	10 years
Gross Carrying Amount	$ 318,000	$ 318,000
Accumulated Amortization	111,000	79,000
Net	$ 207,000	$ 239,000
Licensing Agreements [Member]
Weighted Average Amortization Period (Year)	7 years	7 years
Gross Carrying Amount	$ 432,000	$ 437,000
Accumulated Amortization	424,000	367,000
Net	$ 8,000	$ 70,000
Device Registration [Member]
Weighted Average Amortization Period (Year)	7 years	7 years
Gross Carrying Amount	$ 66,000	$ 66,000
Accumulated Amortization	66,000	66,000
Net
Impairment
Customer Relationships [Member]
Weighted Average Amortization Period (Year)	3 years	3 years
Gross Carrying Amount	$ 442,000	$ 443,000
Accumulated Amortization	442,000	436,000
Net		7,000
Impairment

Note 4 - Intangible Assets an_6

Note 4 - Intangible Assets and Goodwill - Future Amortization Expense (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
2021	$ 40,000
2022	32,000
2023	32,000
2024	32,000
2025	32,000
Thereafter	47,000
Total	$ 215,000	$ 324,000

Note 5 - Equipment and Leaseh_3

Note 5 - Equipment and Leasehold Improvements, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Depreciation, Total	$ 516,000	$ 574,000

Note 5 - Equipment and Leaseh_4

Note 5 - Equipment and Leasehold Improvements, Net - Summary of Property, Plant, and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant, and Equipment, Gross	$ 7,823,000	$ 7,926,000
Less accumulated depreciation	(6,399,000)	(5,898,000)
Total equipment and leasehold improvements, net	1,424,000	2,028,000
Machinery and Equipment [Member]
Property, Plant, and Equipment, Gross	$ 6,004,000	6,107,000
Machinery and Equipment [Member] | Minimum [Member]
Estimated Useful Life (Year)	2 years 182 days
Machinery and Equipment [Member] | Maximum [Member]
Estimated Useful Life (Year)	10 years
Computer and Software [Member]
Property, Plant, and Equipment, Gross	$ 631,000	631,000
Computer and Software [Member] | Minimum [Member]
Estimated Useful Life (Year)	2 years
Computer and Software [Member] | Maximum [Member]
Estimated Useful Life (Year)	5 years
Office Equipment [Member]
Property, Plant, and Equipment, Gross	$ 256,000	256,000
Office Equipment [Member] | Minimum [Member]
Estimated Useful Life (Year)	5 years
Office Equipment [Member] | Maximum [Member]
Estimated Useful Life (Year)	10 years
Leasehold Improvements [Member]
Property, Plant, and Equipment, Gross	$ 932,000	$ 932,000
Leasehold Improvements, Estimated Useful Life	Shorter of 5 years or remaining lease term

Note 6 - Related Party Transa_2

Note 6 - Related Party Transactions (Details Textual) - USD ($)	Apr. 28, 2020	Feb. 29, 2020	Feb. 29, 2020	Mar. 17, 2021	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Mar. 16, 2021	Nov. 26, 2019	Dec. 31, 2018	Apr. 16, 2018	Mar. 31, 2017
Income (Loss) from Equity Method Investments, Total							$ (13,000)	$ (15,000)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total							(16,811,000)	(10,099,000)
Assets, Current, Total							15,298,000	9,521,000
Liabilities, Current, Total							6,143,000	6,685,000
Interest Paid, Excluding Capitalized Interest, Operating Activities							2,379,000	177,000
Amortization of Debt Discount (Premium)							5,558,000	2,349,000
Revenue from Related Parties							39,000	887,000
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member]
Debt Conversion, Original Debt, Amount			$ 3,000,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)			1,666,670
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)											$ 1.80	$ 16.10
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity													$ 10,000,000
Proceeds from Long-term Lines of Credit	$ 2,418,000		$ 1,869,000
Amortization of Accelerated Debt Discount Due to Conversion			$ 2,486,000
Long-term Line of Credit, Total	$ 10,000,000						$ 10,000,000	8,713,000
Debt Instrument, Interest Rate, Stated Percentage							22.00%
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 1,869,000
Amortization of Debt Discount (Premium)							$ 2,931,000	2,344,000
Interest Expense, Debt, Excluding Amortization							2,082,000	1,869,000
Interest Payable							2,082,000	1,869,000
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member] | Subsequent Event [Member]
Interest Paid, Excluding Capitalized Interest, Operating Activities				$ 2,082,000
Boyalife W.S.N. [Member]
Revenue from Related Parties							14,000	794,000
Accounts Receivable, Related Parties							10,000	20,000
COVID-19 Testing Kits [Member]
Inventory Write-down							2,800,000
COVID-19 Testing Kits [Member] | ImmuneCyte [Member]
Related Party Transaction, Purchases from Related Party							$ 3,600,000
Refund from Related Party Purchases					$ 800,000
ImmuneCyte [Member]
Proceeds from Issuance of Common Stock						$ 3,700,000
ImmuneCyte [Member] | Common Class A [Member]
Stock Issued During Period, Shares, New Issues (in shares)						643,750
ImmuneCyte [Member] | Common Class A [Member] | Minimum [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 5	$ 5
ImmuneCyte [Member] | Common Class A [Member] | Maximum [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 16	$ 16
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage					18.79%	18.79%	18.79%			20.00%
Joint Venture Purchase, Percent of Company's Cost										115.00%
Line of Credit Facility, Maximum Borrowing Capacity										$ 1,000,000
Equity Method Investment, Aggregate Cost							$ 0			$ 28,000
Income (Loss) from Equity Method Investments, Total							13,000	$ 15,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total							2,142,000
Assets, Current, Total							1,505,000
Liabilities, Current, Total							$ 410,000
ImmuneCyte [Member] | Subsequent Event [Member]
Equity Method Investment, Ownership Percentage				8.80%					18.79%
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage					75.16%	75.16%				80.00%
ImmuneCyte [Member] | Private Institution [Member]
Equity Method Investment, Ownership Percentage					6.05%	6.05%

Note 7 - Convertible Promisso_3

Note 7 - Convertible Promissory Notes (Details Textual) - USD ($)	Jun. 04, 2020	Jul. 23, 2019	Jan. 29, 2019	Dec. 31, 2020	Dec. 31, 2019	May 30, 2019
Gain (Loss) on Extinguishment of Debt, Total					$ (840,000)
Amortization of Debt Discount (Premium)				5,558,000	2,349,000
Debt Conversion, Converted Instrument, Amount				3,368,000	432,000
Conversion of Convertible Promissory Note to Common Stock [Member]
Debt Conversion, Converted Instrument, Amount				$ 368,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)				204,445
Interest Income (Expense), Nonoperating, Net				$ 46,000
Convertible Debt [Member] | Notes [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger			90.00%
Debt Instrument, Interest Rate, Stated Percentage			24.00%
Debt Instrument, Term (Month)			1 year 180 days
Debt Instrument, Convertible, First Customary Conversion Blockers			4.99%
Debt Instrument, Convertible, Second customary conversion blockers			9.99%
Debt Instrument, Unamortized Discount, Total						$ 800,000
Convertible Debt [Member] | Notes [Member] | Maximum [Member]
Debt Instrument, Face Amount			$ 800,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 1.80
Convertible Debt [Member] | Notes [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 0.50
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger				90.00%
Debt Instrument, Unamortized Discount, Total					556,000
Gain (Loss) on Extinguishment of Debt, Total					840,000
Long-term Debt, Fair Value		$ 1,473,000
Amortization of Debt Discount (Premium)					$ 77,000
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)				$ 1.80
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)				$ 0.50
Convertible Debt [Member] | The July 2019 Note [Member]
Debt Instrument, Face Amount		$ 1,000,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		90.00%
Debt Instrument, Interest Rate, Stated Percentage		24.00%
Debt Conversion, Converted Instrument, Shares Issued (in shares)					240,000
Debt Conversion, Original Debt, Amount					$ 432,000
Interest Income (Expense), Net, Total					$ 60,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 694,000
Convertible Debt [Member] | The July 2019 Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.80
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.50

Note 7 - Convertible Promisso_4

Note 7 - Convertible Promissory Notes - Assumptions (Details) - Convertible Debt [Member]	Jul. 23, 2019
Measurement Input, Share Price [Member]
Long-term Debt, Measurement Input	3.05
Measurement Input, Exercise Price [Member]
Long-term Debt, Measurement Input	1.8	[1]
Measurement Input, Risk Free Interest Rate [Member]
Long-term Debt, Measurement Input	0.018
Measurement Input, Expected Dividend Rate [Member]
Long-term Debt, Measurement Input
Measurement Input, Expected Term [Member]
Long-term Debt, Measurement Input	3.02
Measurement Input, Price Volatility [Member]
Long-term Debt, Measurement Input	0.93
[1]	For the exercise price, the model inputs also accounted for the fair value protection under the Amended Note, which allows for the holder to convert at the lower of $1.80 share or 90% of the listed price of the stock on the day of conversion, whichever is lower (subject to a floor of $0.50).

Note 8 - Payment Protection P_2

Note 8 - Payment Protection Program (Details Textual) - USD ($)	Apr. 21, 2020	Dec. 31, 2020	Dec. 31, 2019
Notes Payable, Current, Total		$ 447,000
Notes Payable, Noncurrent, Total		199,000	$ 1,000,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total	$ 646,000
Notes Payable, Current, Total		447,000
Notes Payable, Noncurrent, Total		$ 199,000

Note 9 - Commitments and Cont_3

Note 9 - Commitments and Contingencies (Details Textual) - USD ($)	May 01, 2020	May 04, 2017	Feb. 29, 2020	Oct. 31, 2017	Dec. 31, 2020	Jul. 13, 2020
Short Term Investment Minimum						$ 1,000,000
Minimum [Member]
Period Of Warranty On Products (Year)					1 year
Maximum [Member]
Period Of Warranty On Products (Year)					2 years
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value		$ 1,000,000
Loss Contingency, Negotiation Condition Bond				$ 1,000,000
Loss Contingency, Damages Awarded, Value			$ 1,000,000
Gain (Loss) Related to Litigation Settlement, Total			(1,400,000)
Litigation Settlement, Expense			1,000,000
Litigation Settlement Interest			$ 400,000
Agreement with Plaintiff For Reimbursement of Trial Related Expenses [Member]
Litigation Settlement, Expense	$ 111,000
Litigation Settlement Interest	369,000
Loss Contingency, Damages Awarded, Value	$ 480,000

Note 9 - Commitments and Cont_4

Note 9 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Beginning balance	$ 277,000	$ 186,000
Warranties originated during the year	71,000	254,000
Claims settled made during the year	(212,000)	(154,000)
Changes in reserve estimate	18,000	(9,000)
Ending balance	$ 154,000	$ 277,000

Note 10 - Leases (Details Textu

Note 10 - Leases (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2019
Operating Lease, Right-of-Use Asset	$ 730,000	$ 859,000
Operating Lease, Payments	301,000	291,000
Operating Lease, Cost	450,000	410,000
Operating Lease, Interest Expense	182,000	204,000
Operating Lease, Right-of-Use Asset, Amortization Expense	129,000	108,000
Variable Lease, Cost	111,000	72,000
Short-term Lease, Cost	$ 28,000	$ 26,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset			$ 966,000

Note 10 - Leases - Lease Inform

Note 10 - Leases - Lease Information (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Right-of-use operating lease assets, net	$ 730,000	$ 859,000
Non-current lease liability	$ 604,000	$ 761,000
Weighted average remaining lease term (Year)	3 years 146 days	4 years 146 days
Discount rate	22.00%	22.00%
Current Liabilities [Member]
Current lease liability	$ 157,000	$ 118,000

Note 10 - Leases - Maturities o

Note 10 - Leases - Maturities of Lease Liabilities (Details)	Dec. 31, 2020USD ($)
2021	$ 310,000
2022	319,000
2023	328,000
2024	139,000
2025
Thereafter
Total lease payment	1,096,000
Less: imputed interest	(335,000)
Present value of operating lease liabilities	$ 761,000

Note 11 - Stockholders' Equit_2

Note 11 - Stockholders' Equity (Details Textual) - USD ($)	Jun. 04, 2020	Mar. 25, 2020	Apr. 18, 2019	Dec. 13, 2020	Dec. 31, 2020	Dec. 31, 2019	May 19, 2020	Dec. 13, 2019	May 30, 2019	Jun. 22, 2018	May 05, 2017
Proceeds from Issuance of Common Stock, Net					$ 10,839,000	$ 756,000
Class of Warrant or Right, Issued During Period (in shares)						444,445
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	565,500				615,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)	$ 5.94				$ 5.92
Share-based Payment Arrangement, Expense					$ 880,000	$ 614,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)					$ 5.05	$ 3.30
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	4 years
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total					$ 2,148,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					3 years
Amended 2016 Plan [Member
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)									3,925,000	1,325,000	600,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)					386,436
Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)					2,500
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)					234
Plan 2012 [Member] | Share-based Payment Arrangement, Option [Member]
Options Prices In Terms Of Fair Market Value					100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					1 year
Equity Incentive Plan 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)					1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)					20,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)					280,000
April 2019 Pre-funded Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)			444,445
Warrants Issued, Price Per Warrant (in dollars per share)			$ 1.70
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		1,000,002
Shares Issued, Price Per Share (in dollars per share)		$ 3.50
Proceeds from Issuance of Common Stock		$ 3,500,000
Payments of Stock Issuance Costs		$ 393,000
At The Market Offering Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)					2,620,652
Proceeds from Issuance of Common Stock					$ 8,224,000
Payments of Stock Issuance Costs					$ 493,000
Maximum Offering Price for Issuance of Common Stock							$ 15,280,313	$ 4,400,000
Shares Issued, Average Price Per Share (in dollars per share)					$ 3.14
Proceeds from Issuance of Common Stock, Net					$ 7,731,000
April 2019 Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.10
Proceeds from Issuance of Warrants			$ 756,000

Note 11 - Stockholders' Equit_3

Note 11 - Stockholders' Equity - Warrant Activity (Details) - $ / shares	11 Months Ended		12 Months Ended
	Dec. 13, 2020	Dec. 13, 2019	Dec. 31, 2019	Dec. 31, 2018
Outstanding (in shares)	1,716,066	1,726,522	1,726,522
Outstanding, weighted average exercise price (in dollars per share)	$ 25.23	$ 29.88	$ 29.88
Outstanding, Weighted Average Remaining Contract Term (Year)	178 days	1 year 208 days	1 year 208 days	2 years 73 days
Warrants granted (in shares)			444,445
Warrants granted, weighted average exercise price (in dollars per share)			$ 0.10
Warrants exercised (in shares)	(599,582)		(435,264)
Warrants exercised, weighted average exercise price (in dollars per share)	$ 2.81		$ 0.35
Warrants expired/canceled (in shares)			(19,637)
Warrants expired/canceled, weighted average exercise price (in dollars per share)
Exercisable (in shares)	1,046,631		1,646,214
Exercisable, weighted average exercise price (in dollars per share)	$ 34.42		$ 22.91
Exercisable, Weighted Average Remaining Contract Term (Year)	197 days		1 year 229 days
Outstanding (in shares)	1,116,484		1,716,066	1,726,522
Outstanding, weighted average exercise price (in dollars per share)	$ 37.27		$ 25.23	$ 29.88

Note 11 - Stockholders' Equit_4

Note 11 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stock-based compensation	$ 880,000	$ 614,000
Cost of Sales [Member]
Stock-based compensation	9,000	3,000
Selling and Marketing Expense [Member]
Stock-based compensation	176,000	185,000
Research and Development Expense [Member]
Stock-based compensation	114,000	98,000
General and Administrative Expense [Member]
Stock-based compensation	$ 581,000	$ 328,000

Note 11 - Stockholders' Equit_5

Note 11 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) - USD ($)	Jun. 04, 2020	Dec. 31, 2020	Dec. 31, 2019
Outstanding, options (in shares)		291,807
Outstanding, weighted average exercise price, options (in dollars per share)		$ 13.96
Outstanding, weighted average remaining contractual life, options (Year)		8 years 255 days	8 years 109 days
Outstanding, aggregate intrinsic value, options			$ 280,000
Granted, options (in shares)	565,500	615,500
Granted, weighted average exercise price, options (in dollars per share)	$ 5.94	$ 5.92
Forfeited/cancelled, options (in shares)		(17,671)
Forfeited, weighted average exercise price, options (in dollars per share)		$ 5.63
Forfeited/cancelled, aggregate intrinsic value, options		$ 1,840
Outstanding, options (in shares)		889,636	291,807
Outstanding, weighted average exercise price, options (in dollars per share)		$ 8.57	$ 13.96
Vested and expected to vest, options (in shares)		598,092
Vested and expected to vest, weighted average exercise price, options (in dollars per share)		$ 9.72
Vested and expected to vest, weighted average remaining contractual life, options (Year)		8 years 182 days
Vested and expected to vest, aggregate intrinsic value, options
Exercisable, options (in shares)		230,836
Exercisable, weighted average exercise price, options (in dollars per share)		$ 15.21
Exercisable, weighted average remaining contractual life, options (Year)		7 years 182 days
Exercisable, aggregate intrinsic value, options

Note 11 - Stockholders' Equit_6

Note 11 - Stockholders' Equity - Non-vested Stock Options Activity (Details) - $ / shares	Jun. 04, 2020	Dec. 31, 2020	Dec. 31, 2019
Outstanding, options (in shares)		291,807
Granted (in shares)	565,500	615,500
Granted, Weighted-Average Grant Date Fair Value (in dollars per share)		$ 5.05	$ 3.30
Cancelled/forfeited (in shares)		(17,671)
Cancelled/forfeited, Weighted-Average Grant Date Fair Value (in dollars per share)		$ 5.63
Outstanding, options (in shares)		889,636	291,807
Non-vested Stock Options [Member]
Outstanding, options (in shares)		144,683
Outstanding, Weighted-Average Grant Date Fair Value (in dollars per share)		$ 6.38
Granted (in shares)		615,500
Granted, Weighted-Average Grant Date Fair Value (in dollars per share)		$ 5.05
Vested (in shares)		(88,683)
Vested, Weighted-Average Grant Date Fair Value (in dollars per share)		$ 5.72
Cancelled/forfeited (in shares)		(12,700)
Cancelled/forfeited, Weighted-Average Grant Date Fair Value (in dollars per share)		$ 4.82
Outstanding, options (in shares)		658,800	144,683
Outstanding, Weighted-Average Grant Date Fair Value (in dollars per share)		$ 5.25	$ 6.38

Note 11 - Stockholders' Equit_7

Note 11 - Stockholders' Equity - Schedule of Assumptions (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Expected life (years) (Year)	6 years	5 years
Expected volatility	116.00%	103.00%
Risk-free interest rate	0.54%	1.68%
Dividend yield	0.00%	0.00%

Note 12 - Concentrations (Detai

Note 12 - Concentrations (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 1,382,000	$ 1,278,000
Revenue from Contract with Customer, Including Assessed Tax	$ 9,705,000	$ 12,160,000
Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member] | Supplier 1 [Member]
Concentration Risk, Percentage	40.00%	57.00%
Customer 1 [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 531,000	$ 337,000
Revenue from Contract with Customer, Including Assessed Tax	$ 2,646,000	$ 3,575,000
Customer 1 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	38.00%	27.00%
Customer 1 [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage	27.00%	27.00%
Distributor 1 [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 337,000	$ 0
Revenue from Contract with Customer, Including Assessed Tax	$ 1,293,000	$ 0
Distributor 1 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	24.00%
Distributor 1 [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage		13.00%
Distributor 2 [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 139,000	$ 93,000
Revenue from Contract with Customer, Including Assessed Tax	$ 283,000	$ 373,000
Distributor 2 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	10.00%	7.00%
Distributor 2 [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage	3.00%	3.00%

Note 12 - Concentrations - Summ

Note 12 - Concentrations - Summary of Net Equipment by Geographic Area (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property, Plant, and Equipment Concentration	$ 1,424,000	$ 2,028,000
Geographic Concentration Risk [Member] | UNITED STATES
Property, Plant, and Equipment Concentration	810,000	1,108,000
Geographic Concentration Risk [Member] | COSTA RICA
Property, Plant, and Equipment Concentration	390,000	582,000
Geographic Concentration Risk [Member] | INDIA
Property, Plant, and Equipment Concentration	169,000	225,000
Geographic Concentration Risk [Member] | All Other Countries [Member]
Property, Plant, and Equipment Concentration	$ 55,000	$ 113,000

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ (16,728,000)	$ (9,949,000)
Income (Loss) from Continuing Operations before Income Taxes, Foreign	(83,000)	(150,000)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	197,000	$ (681,000)
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	126,582,000
Operating Loss Carryforwards, Subject to Expiration	106,226,000
Operating Loss Carryforwards, Not Subject to Expiration	20,356,000
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	1,601,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	41,511,000
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	1,583,000
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total	$ 796,000

Note 13 - Income Taxes - Reconc

Note 13 - Income Taxes - Reconciliation of Federal Income Tax Attributable to Operations to Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statutory federal income tax benefit	$ (3,530,000)	$ (2,118,000)
Intangible assets	69,000	673,000
Change in valuation allowance	197,000	(681,000)
Expiration of net operating losses	1,558,000	1,187,000
Disallowed financing costs	1,619,000	1,119,000
State and local taxes	(18,000)	(205,000)
Other	105,000	25,000
Total income tax expense

Note 13 - Income Taxes - Compon

Note 13 - Income Taxes - Components of Company's Deferred Tax Assets and Liabilities for Federal and State Income Taxes (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Net operating loss carryforwards	$ 27,312,000	$ 26,758,000
Income tax credit carryforwards	2,852,000	2,757,000
Stock compensation	369,000	384,000
Lease obligation	160,000	185,000
Deferred revenue	340,000	419,000
Other	528,000	943,000
Total deferred tax assets	31,561,000	31,446,000
Depreciation and amortization	(352,000)	(408,000)
Lease asset	(153,000)	(180,000)
Total deferred tax liabilities	(505,000)	(588,000)
Valuation allowance	(31,056,000)	(30,858,000)
Net deferred taxes

Note 14 - Employee Retirement_2

Note 14 - Employee Retirement Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan, Plan Assets, Contributions by Employer	$ 147,000	$ 0

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 17, 2021	Dec. 31, 2020	Dec. 31, 2019	Mar. 16, 2021	Sep. 30, 2020	Nov. 26, 2019
Proceeds from Issuance of Common Stock, Net		$ 10,839,000	$ 756,000
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage		18.79%			18.79%	20.00%
Subsequent Event [Member] | ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage	8.80%			18.79%
At The Market Offering Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		2,620,652
Proceeds from Issuance of Common Stock		$ 8,224,000
Shares Issued, Average Price Per Share (in dollars per share)		$ 3.14
Proceeds from Issuance of Common Stock, Net		$ 7,731,000
Payments of Stock Issuance Costs		$ 493,000
At The Market Offering Agreement [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,976,832
Proceeds from Issuance of Common Stock	$ 7,056,000
Shares Issued, Average Price Per Share (in dollars per share)	$ 2.37
Proceeds from Issuance of Common Stock, Net	$ 6,832,000
Payments of Stock Issuance Costs	$ 224,000